Shared on08 Aug 25Fair value Increased 14%
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 58.7x to 65.5x.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 28%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.